112 related articles for article (PubMed ID: 6686692)
1. Longitudinal instability of hormone responses in schizophrenia.
Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Mitton J
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):545-9. PubMed ID: 6686692
[TBL] [Abstract][Full Text] [Related]
2. Noradrenergic and dopaminergic interrelation in schizophrenia.
Brambilla F; Marini S; Saito A; Fassone G; Picardi A; Nerozzi D; Pancheri P
Psychiatry Res; 1994 Sep; 53(3):231-42. PubMed ID: 7870845
[TBL] [Abstract][Full Text] [Related]
3. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
Meltzer HY; Lee MA; Jayathilake K
Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
[TBL] [Abstract][Full Text] [Related]
4. Prolactin and growth hormone responses to growth hormone-releasing hormone in acute schizophrenia.
Nerozzi D; Magnani A; Sforza V; Scaramucci E; Cerilli M; Moretti C; Antonozzi I; Frajese G
Neuropsychobiology; 1990; 23(1):15-7. PubMed ID: 2280826
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms.
Meltzer HY; Kolakowska T; Fang VS; Fogg L; Robertson A; Lewine R; Strahilevitz M; Busch D
Arch Gen Psychiatry; 1984 May; 41(5):512-9. PubMed ID: 6721674
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone responses to apomorphine HCl in schizophrenic patients on drug holidays and at relapse.
Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Dermer SW; MacCrimmon DJ; Mitton J
Br J Psychiatry; 1983 May; 142():482-8. PubMed ID: 6135481
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone responses to graded doses of apomorphine HCl in schizophrenia.
Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Mitton J
Biol Psychiatry; 1983 Aug; 18(8):875-85. PubMed ID: 6137249
[TBL] [Abstract][Full Text] [Related]
8. Multihormonal responses to apomorphine in mental illness.
Mokrani MC; Duval F; Crocq MA; Bailey PE; Macher JP
Psychoneuroendocrinology; 1995; 20(4):365-75. PubMed ID: 8532820
[TBL] [Abstract][Full Text] [Related]
9. Stereospecificity of the dopamine receptor mediating the growth hormone response to apomorphine in man. Short communication.
Lal S; Nair NP; Thavundayil JX; Tawar V; Quirion R; Guyda H
J Neural Transm Gen Sect; 1991; 85(2):157-64. PubMed ID: 1930878
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine.
Kolakowska T; Gelder M; Fraser S
Br J Psychiatry; 1981 Nov; 139():408-12. PubMed ID: 6120733
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine measures of dopaminergic function in chronic cocaine users.
Lee MA; Bowers MM; Nash JF; Meltzer HY
Psychiatry Res; 1990 Aug; 33(2):151-9. PubMed ID: 2243892
[TBL] [Abstract][Full Text] [Related]
12. Schneider's first-rank symptoms of schizophrenia. An association with increased growth hormone response to apomorphine.
Whalley LJ; Christie JE; Brown S; Arbuthnott GW
Arch Gen Psychiatry; 1984 Nov; 41(11):1040-3. PubMed ID: 6497565
[TBL] [Abstract][Full Text] [Related]
13. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
[TBL] [Abstract][Full Text] [Related]
14. Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests.
Duval F; Mokrani MC; Monreal J; Bailey P; Valdebenito M; Crocq MA; Macher JP
Psychoneuroendocrinology; 2003 Jul; 28(5):627-42. PubMed ID: 12727131
[TBL] [Abstract][Full Text] [Related]
15. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
[TBL] [Abstract][Full Text] [Related]
16. Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients.
Zemlan FP; Hirschowitz J; Garver DL
Arch Gen Psychiatry; 1986 Dec; 43(12):1162-7. PubMed ID: 3778112
[TBL] [Abstract][Full Text] [Related]
17. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.
Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
Psychiatry Res; 1992 Mar; 41(3):191-202. PubMed ID: 1594706
[TBL] [Abstract][Full Text] [Related]
18. Elevated response of growth hormone to graded doses of apomorphine in schizophrenic patients.
Müller-Spahn F; Modell S; Ackenheil M; Brachner A; Kurtz G
J Psychiatr Res; 1998; 32(5):265-71. PubMed ID: 9789204
[TBL] [Abstract][Full Text] [Related]
19. Plasma prolactin response to domperidone in acute schizophrenia and schizophreniform illness.
Nerozzi D; Magnani A; Sforza V; Scaramucci E; Cerilli M; Moretti C; Frajese G; Antonozzi I; Meltzer HY
Psychiatry Res; 1990 Nov; 34(2):139-47. PubMed ID: 2149613
[TBL] [Abstract][Full Text] [Related]
20. Behavioral and endocrine responses of schizophrenic patients to TRH (protirelin).
Prange AJ; Loosen PT; Wilson IC; Meltzer HY; Fang VS
Arch Gen Psychiatry; 1979 Sep; 36(10):1086-93. PubMed ID: 112944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
